Oligomerix develops target identification and validation technologies enhancing the drug discovery process for neurodegenerative diseases.
Oligomerix is a biopharmaceutical company founded in 2006 by co-founders Eliot J. Davidowitz and James Moe. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 10, 2022 | Grant | $2.49M | 1 | National Institute on Aging | — | Detail |
Aug 9, 2022 | Grant | $3.35M | 1 | National Institutes of Health | — | Detail |
Jun 2, 2022 | Series B | $2.70M | — | — | — | Detail |
Oct 10, 2019 | Grant | $2.18M | 1 | Small Business Innovation Research | — | Detail |
Apr 15, 2015 | Series Unknown | $400K | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institute on Aging | Yes | Grant |
National Institutes of Health | Yes | Grant |
Small Business Innovation Research | Yes | Grant |
Wheatley MedTech Partners | — | Series A |
Durand Venture Associates | — | Series A |
Wheatley Partners | — | Series A |